Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia

NCT00004654 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Hereditary Hemorrhagic Telangiectasia

Interventions

DRUG: soy protein isolate

Sponsor

National Center for Research Resources (NCRR)

Collaborators

[object Object]